Nifty 500 Multicap 50:25:25 News and Updates

Name: Latest research reports of Larsen & Toubro Ltd. authored by Motilal Oswal and published by - Trendlyne research reports.
Item: Larsen & Toubro Ltd.
Rating: 5
Author: Motilal Oswal

Keep track of all breaking news on Nifty 500 Multicap 50:25:25 from all sources in a single place.

Load latest

Ashok Leyland Ltd.

24 Sep 2025

137.90

-0.53%

Ashok Leyland Share Price Falls As Goldman Sachs Issues Downgrade Details Inside

NDTV Profit

While Ashok Leyland has been a beneficiary of the infrastructure-driven demand for trucks and commercial vehicles as a whole, Goldman Sachs cautioned that demand could taper off in the medium term.

Ashok Leyland Ltd. is trading above all available SMAs

Sun Pharmaceutical Industries Ltd.

24 Sep 2025

1674.60

0.97%

Sun Pharma Is Well Poised To Sustain Growth In Focus Segments, Says Motilal Oswal Maintaining 'Buy'

NDTV Profit

Motilal Oswal expects 14% earnings CAGR over FY25-27E, led by 17% sales CAGR in Sun Pharma's specialty segment and 12% in DF/EM markets, and 160bp margin expansion.

Sun Pharmaceutical Industries Ltd. is trading above its 100 day SMA of 1652.3

Vedanta Ltd.

24 Sep 2025

479.50

-0.97%

Vedanta Engaging With Government After Denial Of Extension For Cambay Basin Oil Block

NDTV Profit

The Anil Agarwal-led company said it is engaging with respective authorities and evaluating all resources available to resolve the matter.

Vedanta Ltd. has gained 29.40% in the last 6 Months

CESC Ltd.

24 Sep 2025

170.98

0.43%

Analysts upgrade CESC; Bull-case target 200 on strong RE, solar mfg push

Business Standard

According to analysts, CESC's bull-case target of 200 assumes timely recovery of regulatory assets (RA) by FY30E, 3.2GW of RE at ~17 per cent RoE, and the new solar manufacturing venture.

CESC Ltd.'s price crossed above 100Day SMA today

Ajanta Pharma Ltd.

24 Sep 2025

2448.00

1.11%

Ajanta Pharma newly rated 'Buy' at PL Capital; 26% upside seen; check TP

Business Standard

The brokerage analysis suggested that branded generics contributed to 74 per cent of Ajanta Pharma's revenue in FY25 and its branded generics business operates with a healthy OPM of 30 per cent

Ajanta Pharma Ltd. is trading below all available SMAs

Nuvama Wealth Management Ltd.

24 Sep 2025

7255.00

1.80%

Minda 2030 Vision: Revenue to hit $2 billion, Nuvama raises target to 620

Business Standard

Minda Corporation's FY30 revenue target of 17,500 cr implies a 28 per cent compound annual growth rate (CAGR) over FY25-30E, while Ebitda is projected at 2,100 cr, reflecting a 30 per cent CAGR.

Number of FII/FPI investors increased from 235 to 266 in Jun 2025 qtr.

Nuvama and Cushman & Wakefield JV to acquire One Paramount property for 2,500 crore

Business Line | 23 Sep 2025 1 more

Larsen & Toubro Ltd.

24 Sep 2025

3783.70

0.38%

Execution momentum to continue

Buy: Larsen & Toubro Ltd.

Target

Motilal Oswal

Our recent meeting with LT reinforces our thesis that execution growth will remain strong for the company over the next few years, driven by a strong order book. The company is selectively eyeing projects from domestic markets and expects international ordering to keep supporting growth.

Number of FII/FPI investors increased from 1104 to 1137 in Jun 2025 qtr.

Hindalco Industries Ltd.

24 Sep 2025

767.00

-0.92%

From hot metal to a firm market; upgrade to BUY

Buy: Hindalco Industries Ltd.

Recommendation Target

Emkay

We upgrade Hindalco to BUY from Reduce, with an increased TP of Rs900 (Rs650 earlier). After the flatlined stock performance in the past 12M, we see HNDL doing well from here.

Hindalco Industries Ltd. has gained 35.99% in the last 6 Months

Minda Corporation Ltd.

24 Sep 2025

587.95

1.01%

Vision 2030 – Targets 3.5x revenue; >25% ROCEs

Buy: Minda Corporation Ltd.

Emkay

We attended Minda’s Analyst Meet and visited Spark Minda Technical Centre (SMIT) in Pune and its Flash Electronics plant; the management outlined its ‘Vision 2030’ at the Meet.

Minda Corporation Ltd. is trading above all available SMAs

Nifty 500 Multicap 50:25:25 PB	3.7
Nifty 500 Multicap 50:25:25 PE	26.3
Nifty 500 Multicap 50:25:25 DIV	1.0
Nifty 500 Multicap 50:25:25 EPS	616.1